We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the last reported quarter, the renowned musculoskeletal healthcare company posted adjusted earnings per share (EPS) of $2.07, beating the Zacks Consensus Estimate by 2.99%. Zimmer Biomet topped earnings estimates in each of the past four quarters, delivering an average surprise of 4.53%.
Q3 Estimates for ZBH
The Zacks Consensus Estimate for the company’s third-quarter revenues is pegged at $2.05 billion, indicating a 2.2% increase from the year-ago reported figure.
The consensus estimate for third-quarter EPS stands at $1.89, suggesting a 0.5% decline year over year. The estimate has remained unchanged over the past 60 days.
Here’s a quick look at the company’s performance leading up to the announcement.
Factors Shaping Zimmer Biomet's Q3 Results
Similar to the previous quarter, Zimmer Biomet’s Knees performance internationally may have been weighed down by China and core emerging markets. However, U.S. performance may have benefited from Oxford Partial Cementless Knee’s unique market position. Continued adoption of newly launched products is also likely to have supported growth.
As part of its brand rationalization strategy, the company has been phasing out its legacy total knee implants such as NexGen and Vanguard, which is expected to have also weighed on overall growth.
The Zacks Consensus Estimate anticipates total Knees revenues to edge down 0.1% year over year.
Zimmer Biomet Holdings, Inc. Price and EPS Surprise
Zimmer Biomet’s Hips business may have also delivered robust performance in the third quarter, supported by demand in both the U.S. and international markets. In the United States, the company is likely to have continued to gain momentum with its hip triple-play of Z1, the OrthoGrid, AI-based hip navigation platform and HAMMR surgical impactor.
The iodine-coated hip launch in Japan has exceeded expectations, with strong demand from both existing surgeons and competitive accounts. The technology is likely to have remained an important growth driver in the third quarter, while Zimmer Biomet may have advanced plans to introduce it in additional markets outside Japan.
The Zacks Consensus Estimate expects total Hips revenues to grow 1.7% year over year.
S.E.T (Sports Medicine, Upper Extremities, Foot and Ankle; Trauma, Craniomaxillofacial and Thoracic) islikely to have extended its solid momentum, helped by Craniomaxillofacial and Thoracic ("CMFT") and Upper Extremities businesses. In the United States, CMFT results benefit from continued strength in its external closure franchise, while Upper Extremities may have gained from growing adoption of its OsseoFit Stemless Shoulder and Identity Total Shoulder platform.However, ongoing challenges in restorative therapies and trauma business may have limited overall S.E.T. growth.
Paragon 28 is likely to have contributed to third-quarter organic revenues, supported by its differentiated product portfolio, strong execution, favorable market dynamics and the successful integration. The acquisition also serves as a model for Zimmer Biomet’s future deals that align strategically and financially, accelerate its weighted average market growth rate (WAMGR) and create a platform for further growth.
The Zacks Consensus Estimate indicates total S.E.T revenues will grow 3% year over year.
In the Technology & Data, Bone Cement and Surgical segment, Zimmer Biomet may have generated strong returns from its comprehensive suite of customer-centric solutions. The company’s capital sales may have benefited from continued demand for ROSA with OptimiZe and TMINI, along with early contributions from the launch of next-generation ROSA Shoulder.
The Zacks Consensus Estimate expects revenues to improve 4.3% year over year.
What Our Model Unveils for ZBH
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here, as you can see below.
Earnings ESP: Zimmer Biomet has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:
Phibro Animal Health (PAHC - Free Report) has an Earnings ESP of +2.10% and a Zacks Rank #2 at present. The company is slated to release first-quarter fiscal 2027 results on Nov. 4.
PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.4%. The Zacks Consensus Estimate for the company’s first-quarter EPS indicates an increase of 8.2% from the year-ago quarter’s figure.
Becton, Dickinson and Company (BDX - Free Report) , or BD, has an Earnings ESP of +0.21% and a Zacks Rank #2 at present. The company is set to release fourth-quarter fiscal 2026 results on Nov. 5.
BD’s earnings beat estimates in each of the trailing four quarters, the average surprise being 2.94%. The Zacks Consensus Estimate for fourth-quarter EPS calls for a rise of 2.5% from the year-ago quarter’s figure.
IDEXX Laboratories (IDXX - Free Report) has an Earnings ESP of +0.59% and a Zacks Rank #2 at present. The company is slated to release third-quarter 2026 results on Nov. 2.
IDXX’s earnings beat estimates in each of the trailing four quarters, the average surprise being 5.7%. The Zacks Consensus Estimate for third-quarter EPS implies a jump of 9.1% from the year-ago quarter’s figure.
View the Zacks #1 Rank List
Image: Bigstock
Zimmer Biomet Gears Up to Report Q3 Earnings: What's in the Cards?
Key Takeaways
Zimmer Biomet (ZBH - Free Report) is set to release third-quarter 2026 results on Nov. 4, before the market opens.
In the last reported quarter, the renowned musculoskeletal healthcare company posted adjusted earnings per share (EPS) of $2.07, beating the Zacks Consensus Estimate by 2.99%. Zimmer Biomet topped earnings estimates in each of the past four quarters, delivering an average surprise of 4.53%.
Q3 Estimates for ZBH
The Zacks Consensus Estimate for the company’s third-quarter revenues is pegged at $2.05 billion, indicating a 2.2% increase from the year-ago reported figure.
The consensus estimate for third-quarter EPS stands at $1.89, suggesting a 0.5% decline year over year. The estimate has remained unchanged over the past 60 days.
Here’s a quick look at the company’s performance leading up to the announcement.
Factors Shaping Zimmer Biomet's Q3 Results
Similar to the previous quarter, Zimmer Biomet’s Knees performance internationally may have been weighed down by China and core emerging markets. However, U.S. performance may have benefited from Oxford Partial Cementless Knee’s unique market position. Continued adoption of newly launched products is also likely to have supported growth.
As part of its brand rationalization strategy, the company has been phasing out its legacy total knee implants such as NexGen and Vanguard, which is expected to have also weighed on overall growth.
The Zacks Consensus Estimate anticipates total Knees revenues to edge down 0.1% year over year.
Zimmer Biomet Holdings, Inc. Price and EPS Surprise
Zimmer Biomet Holdings, Inc. price-eps-surprise | Zimmer Biomet Holdings, Inc. Quote
Zimmer Biomet’s Hips business may have also delivered robust performance in the third quarter, supported by demand in both the U.S. and international markets. In the United States, the company is likely to have continued to gain momentum with its hip triple-play of Z1, the OrthoGrid, AI-based hip navigation platform and HAMMR surgical impactor.
The iodine-coated hip launch in Japan has exceeded expectations, with strong demand from both existing surgeons and competitive accounts. The technology is likely to have remained an important growth driver in the third quarter, while Zimmer Biomet may have advanced plans to introduce it in additional markets outside Japan.
The Zacks Consensus Estimate expects total Hips revenues to grow 1.7% year over year.
S.E.T (Sports Medicine, Upper Extremities, Foot and Ankle; Trauma, Craniomaxillofacial and Thoracic) islikely to have extended its solid momentum, helped by Craniomaxillofacial and Thoracic ("CMFT") and Upper Extremities businesses. In the United States, CMFT results benefit from continued strength in its external closure franchise, while Upper Extremities may have gained from growing adoption of its OsseoFit Stemless Shoulder and Identity Total Shoulder platform.However, ongoing challenges in restorative therapies and trauma business may have limited overall S.E.T. growth.
Paragon 28 is likely to have contributed to third-quarter organic revenues, supported by its differentiated product portfolio, strong execution, favorable market dynamics and the successful integration. The acquisition also serves as a model for Zimmer Biomet’s future deals that align strategically and financially, accelerate its weighted average market growth rate (WAMGR) and create a platform for further growth.
The Zacks Consensus Estimate indicates total S.E.T revenues will grow 3% year over year.
In the Technology & Data, Bone Cement and Surgical segment, Zimmer Biomet may have generated strong returns from its comprehensive suite of customer-centric solutions. The company’s capital sales may have benefited from continued demand for ROSA with OptimiZe and TMINI, along with early contributions from the launch of next-generation ROSA Shoulder.
The Zacks Consensus Estimate expects revenues to improve 4.3% year over year.
What Our Model Unveils for ZBH
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here, as you can see below.
Earnings ESP: Zimmer Biomet has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks Rank #1 stocks here.
Top MedTech Picks
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:
Phibro Animal Health (PAHC - Free Report) has an Earnings ESP of +2.10% and a Zacks Rank #2 at present. The company is slated to release first-quarter fiscal 2027 results on Nov. 4.
PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.4%. The Zacks Consensus Estimate for the company’s first-quarter EPS indicates an increase of 8.2% from the year-ago quarter’s figure.
Becton, Dickinson and Company (BDX - Free Report) , or BD, has an Earnings ESP of +0.21% and a Zacks Rank #2 at present. The company is set to release fourth-quarter fiscal 2026 results on Nov. 5.
BD’s earnings beat estimates in each of the trailing four quarters, the average surprise being 2.94%. The Zacks Consensus Estimate for fourth-quarter EPS calls for a rise of 2.5% from the year-ago quarter’s figure.
IDEXX Laboratories (IDXX - Free Report) has an Earnings ESP of +0.59% and a Zacks Rank #2 at present. The company is slated to release third-quarter 2026 results on Nov. 2.
IDXX’s earnings beat estimates in each of the trailing four quarters, the average surprise being 5.7%. The Zacks Consensus Estimate for third-quarter EPS implies a jump of 9.1% from the year-ago quarter’s figure.